ArticleNeuroImmune pharmacology and therapeutics2023
Quantifying the Neuropsychiatric Symptoms in Post-Acute Sequelae of COVID-19 (PASC) using the NIH Toolbox
Article in NeuroImmune pharmacology and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Transcranial alternating current stimulation for chronic insomnia: a meta-analytic evaluation of sleep restoration and safety in adults.BMC psychiatry · 2026Pooled it
- Long-term neurological and cognitive impact of COVID-19: a systematic review and meta-analysis in over 4 million patients.BMC neurology · 2025Pooled it
- Post-COVID neuropsychiatric symptoms in India: Prevalence, risk factors, and persistence.Indian journal of psychiatry · 2026Article
- Long COVID: lung pathophysiology and its relationship with cognitive dysfunction.Scientific reports · 2025Article
- Structural Brain Abnormalities and Neuropsychiatric Symptoms in Post-COVID Condition.NeuroImmune pharmacology and therapeutics · 2025Article
- Long COVID: Lung Pathophysiology and its Relationship with Cognitive Dysfunction.Research square · 2025Article
- Exploring the Associations between Self-Reported Sleep Disturbance and Cognitive Impairment among Survivors of COVID-19 Hospitalization.Mental health science · 2025Article
- Post-COVID Condition Does Not Alter Cognitive Functions in Young Adults: A Cross-Sectional Study in North India.Cureus · 2025Article
- Elevated cerebral oxygen extraction in patients with post-COVID conditions.NeuroImmune pharmacology and therapeutics · 2024Article
- Neuronal and Glial Metabolite Abnormalities in Participants With Persistent Neuropsychiatric Symptoms After COVID-19: A Brain Proton Magnetic Resonance Spectroscopy Study.The Journal of infectious diseases · 2023Article
- Changes in Brain Activation Patterns During Working Memory Tasks in People With Post-COVID Condition and Persistent Neuropsychiatric Symptoms.Neurology · 2023Article
- Ongoing oxidative stress in individuals with post-acute sequelae of COVID-19.NeuroImmune pharmacology and therapeutics · 2023Article
- Abnormal brain diffusivity in participants with persistent neuropsychiatric symptoms after COVID-19.NeuroImmune pharmacology and therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Objective: To quantify neuropsychiatric symptoms reported by individuals with Post-Acute Sequelae of COVID-19 (PASC) using the NIH Toolbox Methods: 30 PASC (20 women, 21-63 years) and 27 control (16 women, 25-68 years) participants completed three NIHTB batteries and selected PROMIS tests. Group differences on fully corrected T-scores were evaluated using analysis of covariance and Cohen's Results: PASC had poorer emotional health and motor function than controls, including poorer locomotion, endurance and dexterity, but normal cognitive function, ~7 months post-infection, compared to controls. PASC participants had a steeper age-related decline on 2-Minute Walk than controls. T-scores on four cognitive and three motor tests improved with longer time since diagnosis. Conclusion: NIHTB and PROMIS captured the poorer emotional health and motor function in PASC, including the novel findings of deficits locomotion and dexterity. The normal cognitive performance suggests subclinical effects that may be compensated by neural and cognitive reserves, and manifested subjectively by the negative psychological effects and fatigue. The persistent emotional and psychiatric symptoms necessitate mental health treatment be prioritized.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.